Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AMC ENTERTAINMENT HOLDINGS, INC. (AMC) vs Boston Scientific Corporation (BSX) Price & Performance

AMC ENTERTAINMENT HOLDINGS, INC.Trade
Boston Scientific CorporationTrade

Price performance (Past 24H)

Key statistics

AMC ENTERTAINMENT HOLDINGS, INC. vs Boston Scientific Corporation — how do they compare? AMC ENTERTAINMENT HOLDINGS, INC. trades at $2.46 (market cap $2.14B), while Boston Scientific Corporation trades at $50.98 (market cap $74.19B). The key difference: Boston Scientific Corporation is far larger — about 34.7× AMC ENTERTAINMENT HOLDINGS, INC.'s market cap, and AMC ENTERTAINMENT HOLDINGS, INC. pays a 0.11% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.

AMCBSX
Market Cap
$2.14B$74.19B
Sector
MediaHealth
52-Week High
$3.15$108.14
52-Week Low
$0.95$42.63
Enterprise Value
$9.08B$86.27B
Dividend Yield
0.11%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AMC ENTERTAINMENT HOLDINGS, INC.

AMC trades at $2.42, down 6.56% today, yet maintains a bullish technical signal with strong recent earnings beats. The company reported record Q2 2026 revenue and EBITDA, driven by surging attendance and premium screen growth. However, negative net income and substantial debt of $4.01 billion highlight financial strain. Analyst consensus is a $3.00 price target with mixed ratings (32% Buy, 46% Hold).

The outlook hinges on sustained box office recovery and cash flow improvement, with management citing a potential cash-flow breakthrough. Key risks include high leverage, dependence on film slate success, and meme-stock volatility. Upside exists if operational momentum continues, but the negative equity position warrants caution.

Boston Scientific Corporation

BSX trades at $50.46, up 2.33% today, with strong earnings beats in recent quarters and a bullish technical trend. Revenue grew to $20.07B in 2025, with net income margin expanding to 17.5%. The stock shows robust institutional support and insider buying, while facing near-term headwinds from competitive pressures in key segments like WATCHMAN.

Outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target, implying 33% upside. Risks include guidance cuts and market share losses, but solid cash flow and valuation metrics support long-term growth potential for patient investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AMC ENTERTAINMENT HOLDINGS, INC.

AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.

Read more on AMC

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX